As retail investors flock to Viking Therapeutics, the biotech firm is also catching the eye of billionaire fund managers like ...

Shares of Summit Therapeutics, whose cancer drug candidate turned heads after it outperformed a blockbuster drug from Merck, ...

Ginkgo Bioworks is pivoting: Once a synthetic biology darling, the flailing company has now turned to AI-driven protein ...

The new firm is raising a $150 million fund to back startups around science emerging outside Boston and San Francisco.

The Federal Reserve yesterday cut interest rates by 50 basis points, in its first time cutting rates in four years. And how ...

Discover why Inhibrx is a hidden gem in biotech, poised for major growth with innovative treatments. For more investment ...

A rather odd week in venture, as the biggest rounds were raised by greentech, business travel and charity startups. Of course ...

The fall flurry of biotech IPOs shows no signs of abating, with Upstream Bio becoming the latest company to express an ...

BMO Capital Markets managing director of biopharma equity research Evan Seigerman joins Market Domination to discuss the best ...

GC Therapeutics has entered gameplay with the mission of unlocking a new generation of cell therapies, uploading with $75 ...

Industry insiders hope the Fed’s decision to cut rates for the first time in years will boost biotech investment. But the long-awaited move won’t cure all that ails the sector, others cautioned.

Canaccord Genuity analyst John Newman has maintained their bullish stance on ONCY stock, giving a Buy rating yesterday. John Newman has given ...